Jane Street Group LLC Makes New Investment in Silk Road Medical Inc (NASDAQ:SILK)

Jane Street Group LLC bought a new position in Silk Road Medical Inc (NASDAQ:SILK) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,433 shares of the company’s stock, valued at approximately $263,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SILK. Bank of Montreal Can acquired a new stake in Silk Road Medical in the second quarter worth approximately $28,000. Elkfork Partners LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $30,000. Meadow Creek Investment Management LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $36,000. FNY Investment Advisers LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $70,000. Finally, Advisor Group Inc. acquired a new stake in Silk Road Medical in the second quarter worth approximately $78,000. Hedge funds and other institutional investors own 70.18% of the company’s stock.

NASDAQ SILK opened at $31.15 on Friday. Silk Road Medical Inc has a 1 year low of $27.83 and a 1 year high of $51.50. The firm has a fifty day moving average of $36.28. The company has a current ratio of 14.32, a quick ratio of 13.38 and a debt-to-equity ratio of 0.53.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.14). The business had revenue of $14.93 million during the quarter, compared to the consensus estimate of $13.64 million. The company’s revenue was up 92.2% on a year-over-year basis. As a group, analysts anticipate that Silk Road Medical Inc will post -2.02 EPS for the current year.

In other Silk Road Medical news, major shareholder Pincus & Co. Warburg sold 630,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $39.50, for a total value of $24,885,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Several research firms have issued reports on SILK. Zacks Investment Research cut Silk Road Medical from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Argus began coverage on Silk Road Medical in a report on Tuesday, August 20th. They issued a “buy” rating and a $52.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $45.00.

Silk Road Medical Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Read More: Certificate of Deposit (CD) For Risk Adverse Investors?

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.